Search

everythinglearnresearchcommunity

for

Search:↓

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The user has been taking 1mg of finasteride every other day for two months, experiencing improved hair quality but disrupted sleep. They are seeking advice on whether the sleep issues will improve with continued use or if they should stop the medication.

The conversation discusses making oral minoxidil from minoxidil powder as a backup plan due to the unavailability of packaged oral minoxidil in Turkey. The user has a capsule machine and some chemistry knowledge but lacks professional equipment.

The user experienced hair recovery using oral dutasteride 0.5 mg and oral minoxidil 5 mg daily, considering increasing dutasteride dosage but concerned about cost and effectiveness. They noted progress and discussed alternatives like hair transplants and other medications.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

Oral DHT blockers like finasteride are preferred for their ease of use, effectiveness, and long-term safety data, while topical treatments like RU58841 lack extensive safety data and can be more cumbersome to apply. Oral treatments are generally considered more effective and convenient despite potential side effects.

A 28-year-old male using only oral finasteride 1mg since May 15, 2024, reports no side effects and significant hair improvement. He plans to continue finasteride for three more months and is considering adding D3+K2 drops, zinc, folate, and magnesium glycinate.

User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.

Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.

The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

A user experienced side effects from topical ethanol Finasteride and is seeking advice on purchasing liposomal Finasteride in Europe, specifically Germany. They are unsure where to buy it and if it's worth trying.

Crushing spironolactone pills and combining them with minoxidil for topical application may be effective for hair loss, with the addition of finasteride suggested. Adding rosemary and peppermint oils can help mask the unpleasant smell.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A 31-year-old man shared his hair growth progress from July 2024 to March 2026 using oral finasteride (1mg) and minoxidil (2.5mg), with no significant side effects. He is considering switching treatments but is advised to continue with the current regimen due to its effectiveness.

The user plans to switch to oral finasteride and oral minoxidil due to insufficient results from PRP, topical minoxidil, and mild DHT inhibitors. They seek advice on purchasing these medications from My.India, questioning its trustworthiness.

A user started taking finasteride due to increased hair shedding and sought advice on coping with the anxiety of starting the treatment. Responses included personal experiences with finasteride, minoxidil, and tips for integrating the medication into daily routines.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

The user resumed taking 5mg oral minoxidil and 0.5mg dutasteride daily, with vitamins, and noticed hair regrowth. They switched from finasteride to dutasteride due to side effects and prefer oral minoxidil over topical for convenience and effectiveness.

The user reported tiny hair growth in thinning areas and improved thickness after 56 days of using 1 mg oral finasteride, 2.5 mg oral minoxidil, and a serum with Redensyl, Anagain, Capixyl, and Procapil. They also take supplements and maintain a healthy lifestyle with no noticeable side effects.

A 32-year-old is pleased with hair growth results from using oral finasteride (1.2mg) and minoxidil (3mg) without side effects, after switching from topical minoxidil. They report no shedding and increased facial hair density, and they purchase the combo pill from the Hims brand.